A groundbreaking clinical trial has restored partial vision to 26 of 32 patients using a revolutionary combination of retinal implants and smart glasses. Published today in The New England Journal of Medicine, the study represents the most successful vision restoration technology to date, with patients able to read books and complete crossword puzzles after losing central vision to macular degeneration.
Science Corporation just delivered what researchers are calling "amazing" results in the quest to restore sight. The brain-computer interface company's retinal implant system helped 26 out of 32 patients regain functional vision after a full year of testing, marking an 80% success rate that's unprecedented in the vision restoration field.
The breakthrough centers on patients with age-related macular degeneration, a progressive disease that destroys central vision by killing retinal cells. Unlike other forms of blindness, macular degeneration leaves patients with peripheral vision intact but robs them of the ability to read, recognize faces, or perform detailed tasks.
Science Corporation's solution combines a 2-by-2-millimeter implant made of tiny photovoltaic solar panels with camera-equipped smart glasses. The device gets surgically placed under the retina, where it receives near-infrared signals from the glasses and converts them into electrical pulses that stimulate the optic nerve. "Patients could see well enough using the technology to fill out crossword puzzles and read regular books again," researchers reported following the study's publication in The New England Journal of Medicine.
The clinical trial started with 38 patients who received the implants, though only 32 completed the full year of testing. The vision they regained isn't perfect - patients see a blurry, black-and-white version of the world - but it's functional enough to dramatically improve quality of life. Independent researchers called the work "amazing," according to The New York Times.
Behind the technology is Max Hodak, Science Corporation's founder and CEO who previously co-founded Neuralink with Elon Musk in 2016. But this isn't entirely new innovation - Science Corporation acquired the retinal implant technology from French medical device company Pixium Vision in 2024 after Pixium ran out of money following a decade of development work, as reported by IEEE Spectrum.
The acquisition represents a broader trend in the vision prosthetics industry, where promising technologies often outlive their original companies. Second Sight Medical faced a similar fate when it abandoned its technology, only to see it rescued by another medical technology startup that allowed clinical trials to continue.
What makes Science Corporation's approach different is the integration of consumer-grade smart glasses with surgical implants. The glasses capture visual information and transmit it wirelessly to the implanted solar panels, which then generate the electrical signals needed to bypass damaged retinal cells. This hybrid approach leverages advances in both wearable technology and biomedical engineering.
The 80% success rate puts Science Corporation's technology ahead of previous attempts at vision restoration. While patients don't regain normal sight, the functional improvement allows them to navigate daily tasks that were impossible with macular degeneration alone. The black-and-white, low-resolution vision still represents a massive upgrade for people who had lost central vision entirely.
For the broader brain-computer interface industry, these results validate the potential of combining external devices with implanted technology. Unlike pure neural implants that require complex brain surgery, retinal implants offer a less invasive entry point for augmenting human capabilities.
Science Corporation's 80% success rate in restoring functional vision represents a major breakthrough in the brain-computer interface space, proving that hybrid approaches combining wearable devices with surgical implants can deliver real-world results. While the technology still produces limited black-and-white vision, the ability for macular degeneration patients to read and perform detailed tasks again marks a significant step forward in treating irreversible blindness. The success also validates the strategy of acquiring and rescuing promising biotech innovations from financially troubled companies, potentially accelerating the development of other medical technologies.
